Skip to main content
Search
Explore journals
Get published
About BMC
My account
Search all BMC articles
Search
The Journal of Headache and Pain
Home
About
Articles
Submission Guidelines
Submit manuscript
Table 2 (abstract P178). Estimated differences in CFB MMD at 12 weeks in chronic migraine. Values <0 favor eptinezumab. ‘Significance’ at 0.05 threshold should be judged by 95% intervals not crossing 0 and is indicated by an asterisk (*)
From:
16th European Headache Congress 2022 meeting abstracts
Back to article page